Cordner Ryan, Black Keith L, Wheeler Christopher J
CNS Oncol. 2013 Mar;2(2):171-9. doi: 10.2217/cns.12.46.
Glioblastoma multiforme (GBM) is a malignant neoplasm of the CNS with almost uniform lethality. Even with standard-of-care treatments, the prognosis for patients remains dismal. GBM, as with other malignancies, often acquires treatment resistance after an initial response to therapy. Treatment resistance may come about through the adaptive evolution of tumors in response to selection pressures from treatment interventions and the microenvironment. This review discusses how adaptive evolution might potentially be exploited as a new paradigm in GBM treatment.
多形性胶质母细胞瘤（GBM）是一种中枢神经系统的恶性肿瘤，致死率几乎一致。即使采用标准治疗方案，患者的预后仍然很差。与其他恶性肿瘤一样，GBM在对治疗产生初始反应后通常会产生耐药性。耐药性可能是由于肿瘤在治疗干预和微环境的选择压力下适应性进化而产生的。本综述讨论了适应性进化如何有可能被用作GBM治疗的新范式。
